Comprehensive Study Notes on Carbohydrate Metabolism, Glycolysis, Gluconeogenesis, Glycogenesis, and Feeder Pathways

Fundamental Overview of Carbohydrate Metabolism

Carbohydrate metabolism encompasses integrated biochemical pathways that process glucose and other dietary sugars to generate metabolic energy ( $\text{ATP}$ ), supply biosynthetic intermediates, and maintain blood glucose homeostasis.
Glucose serves as a universal, highly versatile biochemical fuel and fundamental precursor across virtually all living organisms.
Four major metabolic pathways dictate the biological utilization of glucose:
- Oxidation via Glycolysis: Converts glucose into pyruvate to extract immediate cellular energy ( $\text{ATP}$ and $\text{NADH}$ ).
- Oxidation via Pentose Phosphate Pathway: Converts glucose into ribose 5-phosphate (for nucleotide synthesis) and generates $\text{NADPH}$ (for reductive biosynthesis and antioxidant defense).
- Storage Pathways: Converts excess glucose into polymeric storage structures, including glycogen in animals and starch or sucrose in plants.
- Structural Polymer Synthesis: Utilizes glucose derivatives to construct structural components of the extracellular matrix and plant/bacterial cell walls.

Four major pathways of glucose utilization

Glucose Transporters (GLUTs and SGLUTs)

The uptake of glucose across plasma membranes into mammalian cells is mediated by specialized membrane transport proteins, comprising facilitated diffusion transporters (GLUT family) and sodium-dependent active symporters (SGLUT family).

Summary table of glucose transporter proteins GLUT-1 through GLUT-5 and SGLUT-1

Detailed Characteristics of Glucose Transport Systems:
- GLUT-1:
- Affinity ( $K_m$ ): $1\,\text{mM}$ (high affinity for glucose).
- Tissue Distribution: Ubiquitously expressed; highly concentrated in red blood cells (RBCs), kidney, colon, and endothelial cells of the blood-brain barrier.
- Insulin Dependence: Independent of insulin.
- GLUT-2:
- Affinity ( $K_m$ ): $15 - 20\,\text{mM}$ (low affinity, high capacity).
- Tissue Distribution: Expressed predominantly in liver hepatocytes and pancreatic $\beta$ -cells.
- Insulin Dependence: Independent of insulin; acts as a dynamic glucose sensor matching intracellular phosphorylation rates to extracellular glucose flux.
- GLUT-3:
- Affinity ( $K_m$ ): $1\,\text{mM}$ (high affinity).
- Tissue Distribution: Primary transporter in tissues metabolically dependent on continuous glucose supply, including neurons, placenta, and testes.
- Insulin Dependence: Independent of insulin.
- GLUT-4:
- Affinity ( $K_m$ ): $5\,\text{mM}$ (close to physiological blood glucose levels).
- Tissue Distribution: Expressed in skeletal muscle, cardiac muscle, and adipose tissue.
- Subcellular Localization and Insulin Dependence: Stored in intracellular vesicles in unstimulated cells; indirectly dependent on insulin (insulin binding triggers vesicle translocation to the plasma membrane to stimulate glucose uptake).
- GLUT-5:
- Functional Specificity: Low capacity for glucose; acts primarily as a specialized transporter for fructose.
- Tissue Distribution: Expressed in the small intestine, testes, sperm cells, and RBCs.
- Insulin Dependence: Independent of insulin.
- SGLUT-1:
- Mechanism: Active secondary co-transporter ( $\text{Glucose}/\text{Na}^+$ symport).
- Tissue Distribution: Expressed on the apical brush border of intestinal epithelia and renal tubule cells.
- Insulin Dependence: Independent of insulin.

Glycolysis (Embden-Meyerhof-Warburg Pathway)

General Characteristics and Bioenergetics:
- Glycolysis is an ubiquitous cytosolic pathway that operates in all body cells to convert one hexose molecule ( $\text{Glucose}$ ) into two triose molecules ( $\text{Pyruvate}$ ).
- Functions under anaerobic conditions (does not require oxygen) to produce net cellular energy ( $\text{ATP}$ ).
- Serves as an emergency energy-producing pathway in tissues experiencing hypoxia (e.g., during fetal birth, oxygen delivery is prioritized for the brain while other tissues rely on glycolysis).
- Serves as the absolute/primary energy source for red blood cells (which lack mitochondria), the brain, eye tissues, and rapidly contracting skeletal muscle during fight-or-flight reactions.
- Pasteur Effect: High concentrations of oxygen ( $\text{O}_2$ ) reduce the rate of glycolytic flux in mitochondria-containing cells, directing pyruvate toward full oxidative phosphorylation.
Overall Net Chemical Equation of Glycolysis: $\text{Glucose} + 2\,\text{ADP} + 2\,\text{NAD}^+ + 2\,\text{P}_i \rightarrow 2\,\text{Pyruvate} + 2\,\text{ATP} + 2\,\text{NADH} + 2\,\text{H}^+ + 2\,\text{H}_2\text{O}$
Three Functional Stages of Glycolysis:
- Stage 1: Trapping and Priming of Glucose
- Involves phosphorylation and isomerization steps that trap glucose inside the cell and prepare it for cleavage.
- Consumes $2\,\text{ATP}$ high-energy phosphate bonds.
- Reaction Equation: $\text{Glucose} + 2\,\text{ATP} \rightarrow \text{Fructose 1,6-bisphosphate} + 2\,\text{ADP} + 2\,\text{H}^+$
- Comprises a series of 3 enzymatic reactions.
- Stage 2: Cleavage of the 6-Carbon Sugar
- Cleaves one 6-carbon sugar phosphate into two readily interconvertible 3-carbon sugar phosphate moieties.
- Reaction Equation: $\text{Fructose 1,6-bisphosphate} \rightarrow \text{DHAP} + \text{GAP}$
- Comprises 1 cleavage reaction and 1 isomerization reaction.
- Stage 3: Harvesting ATP and Oxidation to Pyruvate
- Oxidizes the 3-carbon intermediates, coupled with substrate-level phosphorylation to yield energy.
- Generates $4\,\text{ATP}$ and $2\,\text{NADH}$ .
- Reaction Equation: $2\,\text{GAP} + 4\,\text{ADP} + 2\,\text{P}_i + 2\,\text{H}^+ \rightarrow 2\,\text{Pyruvate} + 4\,\text{ATP} + 2\,\text{H}_2\text{O}$
- Comprises a series of 5 enzymatic reactions.
Detailed Step-by-Step Enzymatic Reactions:
- Preparatory Phase (Reactions 1 to 5):

Preparatory phase of glycolysis showing phosphorylation and cleavage steps

- Reaction 1: Phosphorylation of Glucose (First Priming Reaction)
  - Substrates/Products:  $\text{Glucose} + \text{ATP} \xrightarrow{\text{Mg}^{2+}} \text{Glucose 6-phosphate} + \text{ADP}$ 
  - Enzymes: Hexokinase (I–III) in eukaryotes/extrahepatic tissues; Glucokinase (Hexokinase IV) in liver and pancreatic  $\beta$ -cells.
  - Bioenergetics: Irreversible,  $\Delta G'^{\circ} = -16.7\,\text{kJ/mol}$ . Traps glucose inside the cell as a charged phosphate ester.
- Reaction 2: Isomerization of Glucose 6-Phosphate
  - Substrates/Products:  $\text{Glucose 6-phosphate} \rightleftharpoons \text{Fructose 6-phosphate}$ 
  - Enzyme: Phosphohexose Isomerase (Phosphoglucose Isomerase).
  - Bioenergetics: Reversibly converts an aldose sugar into a ketose sugar.
- Reaction 3: Phosphorylation of Fructose 6-Phosphate (Second Priming Reaction / First Committed Step)
  - Substrates/Products:  $\text{Fructose 6-phosphate} + \text{ATP} \xrightarrow{\text{Mg}^{2+}} \text{Fructose 1,6-bisphosphate} + \text{ADP}$ 
  - Enzyme: Phosphofructokinase-1 (PFK-1).
  - Bioenergetics: Irreversible,  $\Delta G'^{\circ} = -14.2\,\text{kJ/mol}$ . Represents the primary rate-limiting and committed step of glycolysis.
- Reaction 4: Cleavage of Fructose 1,6-Bisphosphate
  - Substrates/Products:  $\text{Fructose 1,6-bisphosphate} \rightleftharpoons \text{Dihydroxyacetone phosphate (DHAP)} + \text{Glyceraldehyde 3-phosphate (GAP)}$ 
  - Enzyme: Aldolase (Fructose 1,6-bisphosphate aldolase).
  - Bioenergetics: Reversible aldol cleavage of a 6-carbon sugar into two distinct 3-carbon triose phosphates.
- Reaction 5: Isomerization of Triose Phosphates
  - Substrates/Products:  $\text{Dihydroxyacetone phosphate (DHAP)} \rightleftharpoons \text{Glyceraldehyde 3-phosphate (GAP)}$ 
  - Enzyme: Triose Phosphate Isomerase.
  - Bioenergetics: Reversibly interconverts DHAP into GAP, allowing both 3-carbon moieties derived from glucose to proceed down the payoff pathway.

Payoff Phase (Reactions 6 to 10):

Payoff phase of glycolysis showing ATP and NADH generation

- Reaction 6: Oxidation and Phosphorylation of GAP
  - Substrates/Products:  $2\,\text{GAP} + 2\,\text{P}_i + 2\,\text{NAD}^+ \rightleftharpoons 2\,\text{(1,3-Bisphosphoglycerate)} + 2\,\text{NADH} + 2\,\text{H}^+$ 
  - Enzyme: Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH).
  - Bioenergetics: Reversible oxidative-phosphorylation; conserves energy in an acyl-phosphate bond and reduces  $\text{NAD}^+$  to  $\text{NADH}$ .
- Reaction 7: First Substrate-Level Phosphorylation
  - Substrates/Products:  $2\,\text{(1,3-Bisphosphoglycerate)} + 2\,\text{ADP} \rightleftharpoons 2\,\text{(3-Phosphoglycerate)} + 2\,\text{ATP}$ 
  - Enzyme: Phosphoglycerate Kinase.
  - Bioenergetics: Reversible substrate-level phosphorylation yielding  $2\,\text{ATP}$  (paying back the  $2\,\text{ATP}$  consumed in the priming phase).
- Reaction 8: Shift of Phosphate Group
  - Substrates/Products:  $2\,\text{(3-Phosphoglycerate)} \rightleftharpoons 2\,\text{(2-Phosphoglycerate)}$ 
  - Enzyme: Phosphoglycerate Mutase.
  - Bioenergetics: Reversible mutase reaction shifting the phosphate group from C-3 to C-2.
- Reaction 9: Dehydration to Phosphoenolpyruvate
  - Substrates/Products:  $2\,\text{(2-Phosphoglycerate)} \rightleftharpoons 2\,\text{Phosphoenolpyruvate (PEP)} + 2\,\text{H}_2\text{O}$ 
  - Enzyme: Enolase.
  - Bioenergetics: Reversible dehydration generating a compound (PEP) with a high-energy phosphate transfer potential.
- Reaction 10: Second Substrate-Level Phosphorylation
  - Substrates/Products:  $2\,\text{PEP} + 2\,\text{ADP} \xrightarrow{\text{Mg}^{2+}, \text{K}^+} 2\,\text{Pyruvate} + 2\,\text{ATP}$ 
  - Enzyme: Pyruvate Kinase.
  - Bioenergetics: Irreversible,  $\Delta G'^{\circ} = -31.4\,\text{kJ/mol}$ . Transfer of phosphate to ADP produces enol-pyruvate, which spontaneously tautomerizes into ketone-pyruvate, releasing large amounts of free energy.

Key Questions and Structural Analysis of Glycolysis:
- Reactions Consuming ATP: Reaction 1 (Hexokinase) and Reaction 3 (PFK-1).
- Reactions Generating ATP: Reaction 7 (Phosphoglycerate kinase) and Reaction 10 (Pyruvate kinase).
- Reaction Generating NADH: Reaction 6 (GAPDH).
- Reaction Involving Carbon-Carbon Bond Cleavage: Reaction 4 (Aldolase).
- Reversible Steps: Reactions 2, 4, 5, 6, 7, 8, and 9.
- Irreversible / Regulated Steps: Reactions 1, 3, and 10.
Metabolic Fates of Pyruvate:
- Aerobic Conditions (Oxygen Present):
- Pyruvate enters the mitochondrial matrix, where it is converted by Pyruvate Dehydrogenase to Acetyl-CoA ( $\text{releasing } \text{CO}_2$ ).
- Acetyl-CoA enters the Citric Acid (TCA) Cycle for complete oxidation to $\text{CO}_2$ and $\text{H}_2\text{O}$ , coupled with high-yield ATP production via oxidative phosphorylation.
- Anaerobic Conditions in Animals and Bacteria (Hypoxia / Strenuous Exercise):
- Pyruvate is reduced to Lactate by Lactate Dehydrogenase in the cytosol.
- Mechanism: Consumes $\text{NADH} + \text{H}^+$ to yield $\text{NAD}^+$ , ensuring the continuous availability of $\text{NAD}^+$ required for Reaction 6 of glycolysis to continue producing ATP in hypoxic muscles or anucleated red blood cells.
- Anaerobic Conditions in Microorganisms (Yeast Fermentation):
- Pyruvate is decarboxylated by Pyruvate Decarboxylase to Acetaldehyde ( $\text{releasing } \text{CO}_2$ ).
- Acetaldehyde is reduced by Alcohol Dehydrogenase to Ethanol, regenerating $\text{NAD}^+$ (utilized in brewing, winemaking, and bread production).
- Amino Acid Biosynthesis:
- Pyruvate undergoes transamination to form Alanine or enters synthetic pathways for Leucine in plants and bacteria.

Gluconeogenesis ("Formation of New Sugar")

Definition and Biological Significance:
- Gluconeogenesis is the biosynthesis of new glucose from non-carbohydrate precursors.
- An energetically expensive anabolic pathway essential for survival in all mammals.
- Critical human tissues require blood glucose as their exclusive or predominant energy substrate, including red blood cells, brain cells, neurons, renal medulla, testes, T-cells during active immune responses, fibroblasts, and embryonic tissues.
Primary Tissue Sites:
- Takes place primarily in the liver (accounting for ~90% of synthesized glucose) and to a lesser extent in the renal cortex of the kidney.
Subcellular Localization:
- Spans multiple cellular compartments: Mitochondria (Pyruvate carboxylase and Malate shunt), Cytosol (PEP to Glucose 6-phosphate steps), and Smooth Endoplasmic Reticulum (Glucose 6-phosphatase).
Major Non-Carbohydrate Precursors:
- Lactate (from anaerobic glycolysis in muscle/RBCs).
- Pyruvate.
- Glucogenic Amino Acids (primarily Alanine derived from muscle protein breakdown).
- Glycerol (liberated from triacylglycerol hydrolysis in adipose tissue).
Net Energetic Cost and Summary Equation:
- Synthesis of 1 molecule of glucose from 2 molecules of pyruvate consumes $4\,\text{ATP}$ , $2\,\text{GTP}$ , and $2\,\text{NADH}$ .
- Summary Chemical Equation: $2\,\text{Pyruvate} + 4\,\text{ATP} + 2\,\text{GTP} + 2\,\text{NADH} + 2\,\text{H}^+ + 4\,\text{H}_2\text{O} \rightarrow \text{Glucose} + 4\,\text{ADP} + 2\,\text{GDP} + 6\,\text{P}_i + 2\,\text{NAD}^+$
Enzymatic Bypasses of the Three Irreversible Glycolytic Steps:
- Bypass 1: Conversion of Pyruvate to Phosphoenolpyruvate (PEP)
- Step 1a: Pyruvate Carboxylase (Mitochondrial Matrix)
  - Reaction: $\text{Pyruvate} + \text{HCO}_3^- + \text{ATP} \rightarrow \text{Oxaloacetate (OAA)} + \text{ADP} + \text{P}_i$
  - Mechanism: Converts a 3-carbon moiety to a 4-carbon moiety. Pyruvate carboxylase contains covalently bound biotin as a prosthetic group that functions as a donor/carrier of activated $\text{CO}_2$
  - Regulation: Obligatorily activated allosterically by Acetyl-CoA. In the absence of Acetyl-CoA, biotin cannot be carboxylated, preventing pyruvate carboxylase activity.
- Malate Shunt (Mitochondrial Transport Mechanism):
  - Oxaloacetate cannot directly cross the inner mitochondrial membrane.
  - OAA is reduced to Malate by mitochondrial Malate Dehydrogenase (consuming mitochondrial $\text{NADH}$ ).
  - Malate is transported out of the mitochondria into the cytosol via a specific dicarboxylate carrier.
  - Cytosolic Malate Dehydrogenase re-oxidizes Malate to OAA, generating cytosolic $\text{NADH}$ required for downstream gluconeogenesis (Reaction 6 reversal).
- Step 1b: Phosphoenolpyruvate Carboxykinase (PEPCK) (Cytosol)
  - Reaction: $\text{Oxaloacetate} + \text{GTP} \rightleftharpoons \text{Phosphoenolpyruvate (PEP)} + \text{CO}_2 + \text{GDP}$
  - Decarboxylation and phosphorylation step requiring $1\,\text{GTP}$ per PEP ( $2\,\text{GTP}$ per glucose).
- Bypass 2: Conversion of Fructose 1,6-Bisphosphate to Fructose 6-Phosphate
- Enzyme: Fructose 1,6-Bisphosphatase (FBPase-1) (Cytosol).
- Reaction: $\text{Fructose 1,6-bisphosphate} + \text{H}_2\text{O} \xrightarrow{\text{Mg}^{2+}} \text{Fructose 6-phosphate} + \text{P}_i$
- Bioenergetics: Irreversible hydrolysis reaction ( $\Delta G'^{\circ} = -16.7\,\text{kJ/mol}$ ). Serves as a major allosteric regulatory node.
- Bypass 3: Conversion of Glucose 6-Phosphate to Free Glucose
- Enzyme: Glucose 6-Phosphatase (Smooth Endoplasmic Reticulum Lumen).
- Reaction: $\text{Glucose 6-phosphate} + \text{H}_2\text{O} \rightarrow \text{Glucose} + \text{P}_i$
- Tissue Distribution & Compartmentalization: Bound to the luminal membrane of the smooth ER. Present only in liver hepatocytes and kidney cortex cells; absent in skeletal muscle and brain. Allows the liver to release free glucose into systemic circulation.
Key Questions and Structural Analysis of Gluconeogenesis:
- Reactions Consuming ATP/GTP: Pyruvate carboxylase ( $2\,\text{ATP}$ ), Phosphoglycerate kinase ( $2\,\text{ATP}$ ), and PEPCK ( $2\,\text{GTP}$ ).
- Reaction Consuming NADH: Glyceraldehyde 3-phosphate dehydrogenase reversal ( $2\,\text{NADH}$ consumed, generating $2\,\text{NAD}^+$ ).
- Compartmental Localization: Pyruvate carboxylase operates in the mitochondria; PEPCK, enolase, mutase, kinase, GAPDH, isomerase, aldolase, and FBPase-1 operate in the cytosol; Glucose 6-phosphatase operates in the smooth ER lumen.

Reciprocal Regulation and Prevention of Futile Cycles

Futile Cycles: Simultaneous, uninhibited activity of opposing glycolytic and gluconeogenic pathways in the same cell would result in a net consumption of ATP/GTP without accomplishing useful biochemical work ("futile cycling").
Three Strategies to Prevent Futile Cycling:
1. Allosteric Regulation: Reciprocal modulation of key rate-limiting enzymes by small-molecule metabolites.
2. Compartmentalization (Compartmental Regulation): Physical segregation of enzyme pools across distinct organelles (e.g., G6Pase inside the ER lumen, Pyruvate carboxylase in mitochondria).
3. Hormonal and Energy Intermediate Control: Reciprocal regulation mediated by insulin/glucagon ratios and energy state indicators ( $\text{ATP}$ , $\text{AMP}$ , $\text{Citrate}$ ).

Reciprocal allosteric regulation of glycolysis and gluconeogenesis in the liver

Specific Reciprocal Allosteric Regulators:
- Fructose 2,6-Bisphosphate ( $\text{F-2,6-BP}$ ):
- PFK-1: Potent allosteric activator ( $+$ ).
- FBPase-1: Potent allosteric inhibitor ( $-$ ).
- Adenosine Monophosphate ( $\text{AMP}$ ):
- PFK-1: Activator ( $+$ ) (signals low energy status).
- FBPase-1: Inhibitor ( $-$ ).
- Adenosine Triphosphate ( $\text{ATP}$ ):
- PFK-1: Inhibitor ( $-$ ) (signals high energy status).
- Pyruvate Kinase: Inhibitor ( $-$ ).
- Citrate:
- PFK-1: Inhibitor ( $-$ ) (signals abundance of TCA cycle precursors).
- FBPase-1: Activator ( $+$ ).
- Protons ( $\text{H}^+$ / Acidosis):
- PFK-1: Inhibitor ( $-$ ).
- Fructose 1,6-Bisphosphate ( $\text{F-1,6-BP}$ ):
- Pyruvate Kinase: Feed-forward activator ( $+$ ), accelerating downstream flux to process incoming sugar phosphates.
- Alanine:
- Pyruvate Kinase: Inhibitor ( $-$ ) (signals available amino acid building blocks for gluconeogenesis).
- Acetyl-CoA:
- Pyruvate Carboxylase: Essential allosteric activator ( $+$ ).
- Adenosine Diphosphate ( $\text{ADP}$ ):
- Pyruvate Carboxylase and PEPCK: Inhibitor ( $-$ ).
Role of the Bifunctional Enzyme (PFK-2 / FBPase-2):
- Fructose 2,6-bisphosphate levels are controlled by a single bifunctional enzyme containing two catalytic domains: Phosphofructokinase-2 (PFK-2) and Fructose 2,6-Bisphosphatase (FBPase-2).
- Abundant Glucose / High Insulin State: Dephosphorylates the bifunctional enzyme, activating PFK-2 domain $\rightarrow$ increases $\text{F-2,6-BP}$ $\rightarrow$ activates PFK-1 $\rightarrow$ stimulates glycolysis.
- Scarce Glucose / High Glucagon State: Protein Kinase A phosphorylates the bifunctional enzyme, activating FBPase-2 domain $\rightarrow$ degrades $\text{F-2,6-BP}$ to F1P $\rightarrow$ relieves FBPase-1 inhibition $\rightarrow$ stimulates gluconeogenesis.

Glycogenesis (Glycogen Synthesis)

Definition and Structure of Glycogen:
- Glycogenesis is the enzymatic synthesis of glycogen from glucose residues during well-fed states.
- Glycogen is a branched homopolysaccharide composed of $\alpha-\text{D-glucose}$ units.
- Main linear chains are joined by $\alpha(1\rightarrow 4)$ glycosidic bonds; branch points occur every 8 to 12 residues joined by $\alpha(1\rightarrow 6)$ glycosidic bonds.
- Stored inside cytoplasm as spherical glycogen granules ( $10 - 40\,\text{nm}$ diameter) aggregated with biosynthetic/degradative enzymes and regulatory machinery.
Primary Storage Sites:
- Liver (~90% of synthesis capacity for blood glucose control) and Skeletal Muscle (~10% by weight, for localized contraction fuel).
Activated Sugar Monomer:
- All glucose residues added to glycogen are provided by Uridine Diphosphate Glucose (UDP-glucose).
Step-by-Step Enzymatic Reactions of Glycogenesis:

Enzymatic steps of glycogenesis including monomer activation and branching

Step 1: Isomerization of Glucose 6-Phosphate
- Substrates/Products: $\text{Glucose 6-phosphate} \rightleftharpoons \text{Glucose 1-phosphate}$
- Enzyme: Phosphoglucomutase.
Step 2: Synthesis of UDP-Glucose and Pyrophosphate Hydrolysis
- Reaction 2a: $\text{Glucose 1-phosphate} + \text{UTP} \rightleftharpoons \text{UDP-Glucose} + \text{PP}_i$
- Enzyme: UDP-Glucose Pyrophosphorylase.
- Reaction 2b: $\text{PP}_i + \text{H}_2\text{O} \rightarrow 2\,\text{P}_i$
- Enzyme: Inorganic Pyrophosphatase.
- Bioenergetics: Rapid, irreversible hydrolysis of inorganic pyrophosphate ( $\text{PP}_i$ ) drives the synthesis of UDP-glucose strongly forward.
Step 3: Primer Formation by Glycogenin
- Glycogen Synthase cannot synthesize glycogen de novo without a pre-existing chain primer.
- Glycogenin is a $34\,\text{kDa}$ dimeric protein core that acts as the auto-catalytic primer.
- Glycogenin attaches a glucose moiety from UDP-glucose to a specific Tyrosine hydroxyl group on itself and elongates it up to ~8 glucose residues.
Step 4: Chain Elongation by Glycogen Synthase
- Enzyme: Glycogen Synthase (Key rate-limiting regulatory enzyme of glycogenesis).
- Reaction: $\text{Glycogen}_n + \text{UDP-Glucose} \rightarrow \text{Glycogen}_{n+1} + \text{UDP}$
- Adds glycosyl residues sequentially onto the non-reducing ends of a pre-existing primer ( $>4$ residues long) via $\alpha(1\rightarrow 4)$ glycosidic bonds.
Step 5: Branching by Glycogen Branching Enzyme
- Enzyme: Glycogen Branching Enzyme ( $\text{Amylo }(1\rightarrow 4) \text{ to } (1\rightarrow 6) \text{ transglycosylase}$ / Glycosyl-(4 $\rightarrow$ 6)-transferase).
- Mechanism: Transfers a terminal chain segment of ~7 glucose residues from a chain at least 11 residues long onto the C-6 hydroxyl group of an internal glucose residue on the same or another chain.
- Biological Significance: Dramatically increases glycogen solubility and creates multiple non-reducing ends for rapid synthesis and breakdown.
- Energetic Cost of Glycogenesis:
Incorporating 1 mole of glucose into glycogen consumes $1\,\text{ATP}$ (hexokinase/glucokinase reaction) plus $1\,\text{UTP}$ (equivalent to ATP), totaling $2\,\text{ATP}$ high-energy equivalents per glucose residue stored.

Glycogenolysis (Glycogen Breakdown)

Functional Role:
- Glycogenolysis is the enzymatic degradation of stored glycogen into glucose 1-phosphate and free glucose during fasting, sleep, or exercise.
Step-by-Step Enzymatic Reactions of Glycogenolysis:
- Step 1: Phosphorolytic Cleavage by Glycogen Phosphorylase
- Enzyme: Glycogen Phosphorylase (Key regulatory enzyme of glycogenolysis).
- Reaction: $\text{Glycogen}_n + \text{P}_i \rightleftharpoons \text{Glycogen}_{n-1} + \text{Glucose 1-phosphate}$
- Mechanism: Cleaves $\alpha(1\rightarrow 4)$ linkages phosphorolytically from non-reducing ends using inorganic phosphate ( $\text{P}_i$ ), conserving chemical energy without consuming ATP.
- Limit Dextrin Formation: Glycogen phosphorylase cannot cleave bonds within 4 residues of an $\alpha(1\rightarrow 6)$ branch point; the remaining structure is termed a limit dextrin.
- Step 2: Debranching Process by Bi-Functional Debranching Enzyme
- Enzyme: Bi-functional Debranching Enzyme ( $4-\alpha-\text{D-glucanotransferase}$ and $\text{Amylo-1,6-glucosidase}$ activities).
- Transferase Action: Moves 3 terminal glucose residues from a 4-residue branch to a non-reducing end of a main chain.
- Glucosidase Action: Hydrolytically cleaves the remaining single $\alpha(1\rightarrow 6)$ -linked glucose residue, releasing one molecule of free, unphosphorylated glucose.
- Step 3: Isomerization to Glucose 6-Phosphate
- Substrates/Products: $\text{Glucose 1-phosphate} \rightleftharpoons \text{Glucose 6-phosphate}$
- Enzyme: Phosphoglucomutase.
- Step 4: Hepatic Glucose Release
- In hepatocytes, Glucose 6-phosphatase in the ER lumen converts Glucose 6-phosphate into free Glucose, which is exported through GLUT2 into the blood.
- Skeletal muscle cells lack Glucose 6-phosphatase; Glucose 6-phosphate enters glycolysis directly to supply contraction energy.
Lysosomal Glycogen Degradation:
- A minor fraction (~1–3%) of cellular glycogen is continuously degraded in lysosomes by Lysosomal $\alpha-1,4-\text{glucosidase}$ (Acid Maltase).

Liver Homeostasis, Glucokinase vs. Hexokinase, and Metabolic Signalling

Comparative Properties of Hexokinase vs. Glucokinase (Hexokinase IV):
- Distribution:
- Hexokinase (Types I–III): Present in all body tissues (ubiquitous).
- Glucokinase (Hexokinase IV): Present exclusively in liver hepatocytes and pancreatic $\beta$ -cells.
- Substrate Affinity ( $K_m$ ):
- Hexokinase: Very high affinity ( $K_m \sim 0.05\,\text{mmol/L}$ or $0.1\,\text{mM}$ ); operates at maximal velocity ( $V_{max}$ ) under basal glucose levels.
- Glucokinase: Low affinity ( $K_m \sim 5.5\,\text{mmol/L}$ to $10\,\text{mM}$ ); activity rises proportionally following carbohydrate-rich meals.
- Feedback Inhibition:
- Hexokinase: Strongly inhibited by its product, Glucose 6-phosphate (negative feedback control).
- Glucokinase: NOT inhibited by Glucose 6-phosphate; allows continuous glucose trapping during hyper-glycemic states.
- Substrate Broadness:
- Hexokinase: Acts on glucose, fructose, and mannose.
- Glucokinase: Specific exclusively for glucose.
- Hormonal Inducibility:
- Hexokinase: Non-inducible.
- Glucokinase: Inducible by insulin and high glucose diets.
Fed vs. Fasting Liver Decision Machinery:
- Fed State (High Blood Glucose / High Insulin):
- Glucokinase traps large amounts of glucose as Glucose 6-phosphate.
- High Glucose 6-phosphate activates Glycogen Synthase while inhibiting Glycogen Phosphorylase, directing flux into glycogenesis.
- Fasting State (Low Blood Glucose / High Glucagon):
- Glucagon raises $\text{cAMP}$ , activating Protein Kinase A.
- PKA phosphorylates Glycogen Phosphorylase Kinase (activating Glycogen Phosphorylase) and phosphorylates Glycogen Synthase (inactivating it), driving glycogenolysis.

Inter-Organ Metabolic Cycles

Cori Cycle (Lactic Acid Cycle):

Cori cycle inter-organ metabolic flux between liver and red blood cells or muscle

Pathway Flow:
- Anaerobic glycolysis in skeletal muscle or red blood cells converts Glucose to $2\,\text{Lactate}$ , yielding $2\,\text{ATP}$ .
- Lactate diffuses into the bloodstream and travels to the liver.
- Hepatocytes convert $2\,\text{Lactate}$ back into Glucose via gluconeogenesis, consuming $6\,\text{ATP}$ equivalents ( $4\,\text{ATP} + 2\,\text{GTP}$ ).
- Glucose is released back into circulation to be reused by peripheral tissues.
Bioenergetic Net Balance:
- Peripheral Tissue Gain: $+2\,\text{ATP}$ .
- Liver Cost: $-6\,\text{ATP}$ .
- Net Organismal Energy Balance: Net loss of $-4\,\text{ATP}$ per cycle turn.
Biological Significance:
- Prevents systemic lactic acidosis during intense anaerobic exertion.
- Shifts the bioenergetic burden of supporting anaerobic tissue survival onto the liver.
- Glucose-Alanine Cycle:
Pyruvate produced in active skeletal muscle undergoes transamination to Alanine.
Alanine travels through the blood to the liver, where it is transaminated back to Pyruvate for gluconeogenesis, while its amino group is safely eliminated via the Urea Cycle.

Glycogen Storage Diseases (GSDs) and Associated Metabolic Disorders

Classification and Clinical Characteristics of Selected Inborn Errors:
- Type 0: Glycogen Synthase Deficiency (GSD 0)
- Deficient Enzyme: Glycogen Synthase.
- Pathophysiology: Inability to synthesize glycogen in the liver.
- Clinical Features: Severe fasting hypoglycemia during sleep, total reliance on dietary carbohydrate intake, requirement for frequent feedings, periodic muscle cramping.
- Type I: Von Gierke's Disease (GSD I)
- Deficient Enzyme: Glucose 6-Phosphatase (Type Ia) or Glucose 6-Phosphate Translocase (Type Ib).
- Affected Organs: Liver and kidney cortex.
- Glycogen Structure & Quantity: Normal glycogen structure; massive accumulation in tissue storage.
- Clinical Features: Severe fasting hypoglycemia, failure of glycogenolysis and gluconeogenesis to release glucose, massive hepatomegaly, severe lactic acidosis (high pyruvate shunted to lactate), hyperlipidemia (elevated glucagon drives lipolysis and lipogenesis), ketosis, hyperuricemia with gouty arthritis (impaired renal uric acid excretion due to lactic acid competition, combined with purine degradation), short stature, doll-like facies, protruding abdomen with emaciated extremities.
- Type II: Pompe Disease (GSD II)

Pompe disease pathophysiology, diagnostic methods, and clinical features

- Deficient Enzyme: Lysosomal  $\alpha-1,4-\text{glucosidase}$  (Acid Maltase / Acid  $\alpha$ -glucosidase), caused by GAA gene mutations. Autosomal recessive inheritance.
- Pathophysiology: Inability to degrade glycogen inside lysosomes; massive glycogen accumulation within membrane-bound lysosomal inclusion bodies across all tissues.
- Clinical Subtypes:
  - Infantile-Onset: Severe hypertrophic cardiomyopathy, cardiomegaly, respiratory failure, severe muscle hypotonia, early death (before 2 years of age).
  - Late-Onset: Progressive skeletal muscle weakness; does not involve the heart at any age.
- Diagnosis & Treatment: Blood test measuring GAA enzyme activity. Treated via Enzyme Replacement Therapy (ERT) and supportive management.

Type III: Cori's Disease / Forbes Disease (GSD IIIa)
- Deficient Enzyme: Debranching Enzyme ( $\text{Amylo-1,6-glucosidase}$ ).
- Affected Organs: Liver, skeletal muscle, cardiac muscle.
- Glycogen Structure: Abnormal glycogen with extremely short outer branches containing single glucose residues (limit dextrin accumulation).
- Clinical Features: Mild fasting hypoglycemia, hepatomegaly, liver enlargement, muscle weakness.
Type IV: Andersen Disease (GSD IV)
- Deficient Enzyme: Glycogen Branching Enzyme ( $\alpha-1,4 \rightarrow \alpha-1,6$ ).
- Affected Organs: Liver and spleen (hepatosplenomegaly).
- Glycogen Structure: Abnormal glycogen with unbranched long outer chains and very few branch points toward the periphery.
- Clinical Features: Progressive liver cirrhosis, scarring, infantile hypotonia, liver failure, early death (before 2 years of age).
Type V: McArdle's Disease (GSD V)
- Deficient Enzyme: Muscle Glycogen Phosphorylase.
- Affected Organ: Skeletal muscle.
- Glycogen Structure: Normal glycogen structure.
- Clinical Features: Painful muscle cramps during exercise, exercise intolerance, myoglobinuria. During exercise, muscle pH becomes alkaline (rather than acidic) due to creatine phosphate breakdown without lactate production; high ADP levels; Cori cycle impaired.
Type VI: Hers' Disease (GSD VI)
- Deficient Enzyme: Hepatic Glycogen Phosphorylase.
- Affected Organ: Liver.
- Glycogen Structure: Normal glycogen structure.
- Clinical Features: Mild fasting hypoglycemia, hepatomegaly.
Type VII: Tarui Disease (GSD VII)
- Deficient Enzyme: Phosphofructokinase (PFK-1) in muscle and red blood cells.
Additional GSD Classifications:
- GSD IX: Phosphorylase Kinase deficiency.
- GSD X: Phosphoglycerate Mutase deficiency.
- GSD XI: Lactate Dehydrogenase deficiency / GLUT2 deficiency (Fanconi-Bickel syndrome).
- GSD XII: Aldolase A deficiency.
- GSD XIII: Enolase 3 deficiency.
- GSD XV: Glycogenin deficiency.

Feeder Pathways of Glycolysis

Digestion and Absorption of Dietary Carbohydrates:
- Starch Degradation: $\alpha(1\rightarrow 4)$ and $\alpha(1\rightarrow 6)$ bonds in starch are cleaved by salivary/pancreatic $\alpha$ -amylase, maltase, isomaltase, and glucoamylase into glucose.
- Sucrose Hydrolysis: Catalyzed by Sucrase (Invertase) or acid to yield Glucose + Fructose ("invert sugar", sweeter than sucrose).
- Lactose Hydrolysis: Catalyzed by intestinal lactase to yield Galactose + Glucose.
Entry Points for Other Monosaccharides into Glycolysis:
- Mannose Pathway:
- Phosphorylated by Hexokinase to Mannose 6-phosphate ( $\text{Man 6-P}$ ).
- Reversibly isomerized by Phosphomannose Isomerase to Fructose 6-phosphate ( $\text{F 6-P}$ ), entering glycolysis.
- Fructose Pathways:
- Muscle / Adipose Pathway: Phosphorylated directly by Hexokinase to Fructose 6-phosphate ( $\text{F 6-P}$ ). Minor pathway due to strong competition with glucose.
- Hepatic Pathway (Primary Fructose Metabolism):
  - Transported into hepatocytes via GLUT2.
  - Phosphorylated by Fructokinase (Ketohexokinase) using ATP to Fructose 1-phosphate ( $\text{F 1-P}$ ).
  - Cleaved by Aldolase B into Dihydroxyacetone phosphate (DHAP) + Glyceraldehyde.
  - Glyceraldehyde is phosphorylated by Triokinase using ATP to Glyceraldehyde 3-phosphate (GAP).
  - Critical Pathophysiological Advantage/Disadvantage: Bypasses Phosphofructokinase-1 (PFK-1), the primary regulatory control point of glycolysis.
Pathophysiological Consequences of Excessive Hepatic Fructose Metabolism:

Pathophysiological consequences of uncontrolled hepatic fructose metabolism

Rapid Hepatic ATP Depletion and Hyperuricemia:
- Rapid phosphorylation of fructose by fructokinase consumes ATP uncontrollably, lowering intracellular inorganic phosphate ( $\text{P}_i$ ).
- Accumulating $\text{AMP}$ triggers $\text{AMP}$ degradation pathways, leading to excessive uric acid production (hyperuricemia) and gout.
Triose-Phosphate Overflow and Lactic Acidosis:
- Massive conversion of fructose into triose-phosphates overflows downstream metabolic pathways, resulting in elevated lactate production (lactic acidosis).
Excessive De Novo Lipogenesis (DNL) and Fatty Liver:
- Excess triose-phosphates yield abundant pyruvate and Acetyl-CoA, driving De Novo Lipogenesis (DNL).
- Increases synthesis of free fatty acids, triacylglycerols (TAG), VLDL, and cholesterol, resulting in hyperlipidemia and Non-Alcoholic Fatty Liver Disease (Fatty Liver).

Inborn Errors of Fructose Metabolism:
- Essential Fructosuria:
- Deficient Enzyme: Fructokinase (Ketohexokinase).
- Clinical Phenotype: Rare, benign, asymptomatic condition. Fructose cannot be phosphorylated in the liver and accumulates in blood (fructosemia) and urine (fructosuria).
- Hereditary Fructose Intolerance (HFI) / Fructosemia:
- Deficient Enzyme: Aldolase B.
- Clinical Phenotype: Fructose 1-phosphate accumulates in hepatocytes, trapping intracellular inorganic phosphate ( $\text{P}_i$ ).
- Pathophysiology: Phosphate trapping depletes ATP and inhibits glycogen phosphorylase and gluconeogenesis, causing severe hypoglycemia, vomiting, jaundice, hepatomegaly, renal dysfunction, and liver failure following ingestion of fructose, sucrose, or sorbitol.
Galactose Metabolism (Leloir Pathway):
- Ingested Lactose is hydrolyzed by Lactase into Glucose and Galactose.
- Enzymatic Steps:
1. Galactose is phosphorylated by Galactokinase using ATP to Galactose 1-phosphate ( $\text{Gal 1-P}$ ).
2. Galactose 1-Phosphate Uridylyltransferase (GALT) converts $\text{Gal 1-P} + \text{UDP-Glucose} \rightleftharpoons \text{Glucose 1-P} + \text{UDP-Galactose}$ .
3. UDP-Hexose 4-Epimerase converts UDP-Galactose back into UDP-Glucose.
4. Phosphoglucomutase converts Glucose 1-phosphate into Glucose 6-phosphate for glycolytic or gluconeogenic entry.
Disorders of Galactose Metabolism:

Clinical and enzymatic features of Galactokinase deficiency and Classic Galactosemia

Lactose Intolerance:
- Cause: Deficiency of brush-border Lactase enzyme in the small intestine.
- Phenotype: Inability to digest lactose, causing osmotic diarrhea, abdominal cramps, and flatulence.
Galactokinase Deficiency:
- Cause: Deficient Galactokinase enzyme. Rare autosomal recessive disorder.
- Phenotype: Elevation of galactose in blood (galactosemia) and urine (galactosuria). Excess galactose is reduced by Aldose Reductase (using $\text{NADPH}$ ) to Galactitol in lens tissue, causing severe cataracts. Managed via strict dietary restriction of galactose and lactose.
Classic Galactosemia:
- Cause: Deficiency of Galactose 1-Phosphate Uridylyltransferase (GALT). Autosomal recessive disorder ( $1:30,000$ live births).
- Phenotype: Accumulation of Galactose 1-phosphate and Galactitol in nerve, lens, liver, and kidney tissues.
- Clinical Features: Severe jaundice, vomiting, diarrhea, hepatomegaly, liver damage, cataracts, and severe mental retardation. Females remain at risk for premature ovarian failure and developmental delays despite early dietary management. Diagnosed via prenatal chorionic villus sampling or newborn screening.